DOXIL®
(doxorubicin HCl liposome injection) for Intravenous Infusion
INFUSION REACTIONS, MYELOSUPPRESSION, CARDIOTOXICITY, LIVER IMPAIRMENT, ACCIDENTAL SUBSTITUTION
DOXIL (doxorubicin HCl liposome injection) is doxorubicin hydrochloride (HCl) encapsulated in STEALTH® liposomes for intravenous administration.
Doxorubicin is an anthracycline topoisomerase inhibitor isolated from Streptomyces peucetius var. caesius.
Doxorubicin HCl, which is the established name for (8S,10S)-10-[(3-amino-2,3,6-trideoxyα- L-lyxo-hexopyranosyl)oxy]-8-glycolyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy5,12- naphthacenedione hydrochloride, has the following structure:
 |
The molecular formula of the drug is C27H29NO11•HCl; its molecular weight is 579.99.
DOXIL is provided as a sterile, translucent, red liposomal dispersion in 10-mL or 30-Ml glass, single use vials. Each vial contains 20 mg or 50 mg doxorubicin HCl at a concentration of 2 mg/mL and a pH of 6.5. The STEALTH® liposome carriers are composed of N-(carbonyl-methoxypolyethylene glycol 2000)-1,2-distearoyl-sn-glycero3- phosphoethanolamine sodium salt (MPEG-DSPE), 3.19 mg/mL; fully hydrogenated soy phosphatidylcholine (HSPC), 9.58 mg/mL; and cholesterol, 3.19 mg/mL. Each mL also contains ammonium sulfate, approximately 2 mg; histidine as a buffer; hydrochloric acid and/or sodium hydroxide for pH control; and sucrose to maintain isotonicity. Greater than 90% of the drug is encapsulated in the STEALTH® liposomes.
MPEG-DSPE has the following structural formula:
 |
HSPC has the following structural formula:
 |
Last updated on RxList: 7/8/2008
DOXIL (doxorubicin HCl liposome injection) is indicated for the treatment of patients with ovarian cancer whose disease has progressed or recurred after platinum-based chemotherapy.
DOXIL is indicated for the treatment of AIDS-related Kaposi's sarcoma in patients after failure of prior systemic chemotherapy or intolerance to such therapy.
DOXIL in combination with bortezomib is indicated for the treatment of patients with multiple myeloma who have not previously received bortezomib and have received at least one prior therapy.
Liposomal encapsulation can substantially affect a drug's functional properties relative to those of the unencapsulated drug. Therefore DO NOT SUBSTITUTE one drug for the other.
Do not administer as a bolus injection or an undiluted solution. Rapid infusion may increase the risk of infusion-related reactions [see WARNINGS and PRECAUTIONS]. DOXIL must not be given by the intramuscular or subcutaneous route.
Until specific compatibility data are available, it is not recommended that DOXIL be mixed with other drugs.
DOXIL should be considered an irritant and precautions should be taken to avoid extravasation. With intravenous administration of DOXIL, extravasation may occur with or without an accompanying stinging or burning sensation, even if blood returns well on aspiration of the infusion needle. If any signs or symptoms of extravasation have occurred, the infusion should be immediately terminated and restarted in another vein. The application of ice over the site of extravasation for approximately 30 minutes may be helpful in alleviating the local reaction.
DOXIL (doxorubicin HCl liposome injection) should be administered intravenously at a dose of 50 mg/m² (doxorubicin HCl equivalent) at an initial rate of 1 mg/min to minimize the risk of infusion reactions. If no infusion-related adverse reactions are observed, the rate of infusion can be increased to complete administration of the drug over one hour. The patient should be dosed once every 4 weeks, for as long as the patient does not progress, shows no evidence of cardiotoxicity [see WARNINGS and PRECAUTIONS], and continues to tolerate treatment. A minimum of 4 courses is recommended because median time to response in clinical trials was 4 months. To manage adverse reactions such as hand-foot syndrome (HFS), stomatitis, or hematologic toxicity the doses may be delayed or reduced [see DOSAGE AND ADMINISTRATION]. Pretreatment with or concomitant use of antiemetics should be considered.
DOXIL (doxorubicin HCl liposome injection) should be administered intravenously at a dose of 20 mg/m² (doxorubicin HCl equivalent). An initial rate of 1 mg/min should be used to minimize the risk of infusion-related reactions. If no infusion-related adverse reactions are observed, the infusion rate should be increased to complete the administration of the drug over one hour. The dose should be repeated once every three weeks, for as long as patients respond satisfactorily and tolerate treatment.
Bortezomib is administered at a dose of 1.3 mg/m² as intravenous bolus on days 1, 4 , 8 and 11, every three weeks. DOXIL 30 mg/m² should be administered as a 1-hr intravenous infusion on day 4 following bortezomib. With the first DOXIL dose, an initial rate of 1 mg/min should be used to minimize the risk of infusion-related reactions. If no infusion-related adverse reactions are observed, the infusion rate should be increased to complete the administration of the drug over one hour. Patients may be treated for up to 8 cycles until disease progression or the occurrence of unacceptable toxicity.
DOXIL exhibits nonlinear pharmacokinetics at 50 mg/m²; therefore, dose adjustments may result in a non-proportional greater change in plasma concentration and exposure to the drug [see CLINICAL PHARMACOLOGY].
Patients should be carefully monitored for toxicity. Adverse reactions, such as HFS, hematologic toxicities, and stomatitis may be managed by dose delays and adjustments. Following the first appearance of a Grade 2 or higher adverse reactions, the dosing should be adjusted or delayed as described in the following tables. Once the dose has been reduced, it should not be increased at a later time.
Table 1: Hand-Foot Syndrome (HFS)
| Toxicity Grade | Dose Adjustment |
1 (mild erythema, swelling, or desquamation not interfering with daily activities) |
Redose unless patient has experienced previous Grade 3 or 4 HFS. If so, delay up to 2 weeks and decrease dose by 25%. Return to original dose interval. |
| 2 (erythema, desquamation, or swelling interfering with, but not precluding normal physical activities; small blisters or ulcerations less than 2 cm in diameter) | Delay dosing up to 2 weeks or until resolved to Grade 0-1. If after 2 weeks there is no resolution, DOXIL should be discontinued. If resolved to Grade 0-1 within 2 weeks, and there are no prior Grade 3-4 HFS, continue treatment at previous dose and return to original dose interval. I f patient experienced previous Grade 3-4 toxicity, continue treatment with a 25% dose reduction and return to original dose interval. |
| 3 (blistering, ulceration, or swelling interfering with walking or normal daily activities; cannot wear regular clothing) |
Delay dosing up to 2 weeks or until resolved to Grade 0-1. Decrease dose by 25% and return to original dose interval. If after 2 weeks there is no resolution, DOXIL should be discontinued. |
| 4 (diffuse or local process causing infectious complications, or a bed ridden state or hospitalization) | Delay dosing up to 2 weeks or until resolved to Grade 0-1. Decrease dose by 25% and return to original dose interval. If after 2 weeks there is no resolution, DOXIL should be discontinued. |
Table 2: Hematological Toxicity
| Grade | ANC | Platelets | Modification |
| 1 | 1,500 - 1,900 | 75,000 - 150,000 | Resume treatment with no dose reduction |
| 2 | 1,000 - < 1,500 | 50,000 - < 75,000 | Wait until ANC ≥ 1,500 and platelets ≥ 75,000; redose with no dose reduction |
| 3 | 500 - 999 | 25,000 - < 50,000 | Wait until ANC ≥ 1,500 and platelets ≥ 75,000; redose with no dose reduction |
| 4 | < 500 | < 25,000 | Wait until ANC ≥ 1,500 and platelets ≥ 75,000; redose at 25% dose reduction or continue full dose with cytokine support |
Table 3: Stomatitis
| Toxicity Grade | Dose Adjustment |
| 1 (painless ulcers, erythema, or mild soreness) | Redose unless patient has experienced previous Grade 3 or 4 toxicity. If so, delay up to 2 weeks and decrease dose by 25%. Return to original dose interval. |
| 2 (painful erythema, edema, or ulcers, but can eat) | Delay dosing up to 2 weeks or until resolved to Grade 0-1. If after 2 weeks there is no resolution, DOXIL should be discontinued. If resolved to Grade 0-1 within 2 weeks and there was no prior Grade 3-4 stomatitis, continue treatment at previous dose and return to original dose interval. If patient experienced previous Grade 3-4 toxicity, continue treatment with a 25% dose reduction and return to original dose interval. |
| 3 (painful erythema, edema, or ulcers, and cannot eat) | Delay dosing up to 2 weeks or until resolved to Grade 0-1. Decrease dose by 25% and return to original dose interval. If after 2 weeks there is no resolution, DOXIL should be discontinued. |
| 4 (requires parenteral or enteral support) | Delay dosing up to 2 weeks or until resolved to Grade 0-1. Decrease dose by 25% and return to DOXIL original dose interval. If after 2 weeks there is no resolution, DOXIL should be discontinued. |
For patients treated with DOXIL in combination with bortezomib who experience handfoot syndrome or stomatitis, the DOXIL dose should be modified as described in Tables 1 and 3 above. Table 4 describes dosage adjustments for DOXIL and bortezomib combination therapy. For bortezomib dosing and dosage adjustments, see manufacturer's prescribing information.
Table 4: Dosage adjustments for DOXIL + bortezomib combination
therapy
| Patient status | DOXIL | bortezomib |
| Fever ≥ 38°C and ANC < 1,000/mm³ | Do not dose this cycle if before Day 4; if after Day 4, reduce next dose by 25%. | Reduce next dose by 25% |
| On any day of drug administration after Day 1 of each cycle: 3 Platelet count < 25,000/mm³ Hemoglobin < 8g/dL 3 ANC < 500/mm³ | Do not dose this cycle if before Day 4; if after Day 4 reduce next dose by 25% in the following cycles if bortezomib is reduced for hematologic toxicity. | Do not dose; if 2 or more doses are not given in a cycle, reduce dose by 25% in following cycles. |
| Grade 3 or 4 non-hematologic drug related toxicity | Do not dose until recovered to Grade < 2 and reduce dose by 25% for all subsequent doses. | Do not dose until recovered to Grade <2 and reduce dose by 25% for all subsequent doses. |
| Neuropathic pain or peripheral neuropathy | No dosage adjustments. | See bortezomib prescribing information for dosage adjustments in patients with neuropathic pain. |
Limited clinical experience exists in treating patients with hepatic impairment with DOXIL. Based on experience with doxorubicin HCl, it is recommended that the DOXIL dosage be reduced if the bilirubin is elevated as follows: serum bilirubin 1.2 to 3.0 mg/dL - give ½ normal dose; serum bilirubin > 3 mg/dL - give ¼ normal dose.
No information, including dosage adjustments, is available for patients with multiple myeloma with hepatic impairment.
Each 10-mL vial contains 20 mg doxorubicin HCl at a concentration of 2 mg/mL.
Each 30-mL vial contains 50 mg doxorubicin HCl at a concentration of 2 mg/mL.
DOXIL doses up to 90 mg must be diluted in 250 mL of 5% Dextrose Injection, USP prior to administration. Doses exceeding 90 mg should be diluted in 500 mL of 5% Dextrose Injection, USP prior to administration. Aseptic technique must be strictly observed since no preservative or bacteriostatic agent is present in DOXIL. Diluted DOXIL should be refrigerated at 2°C to 8°C (36°F to 46°F) and administered within 24 hours.
Do not use with in-line filters.
Do not mix with other drugs.
Do not use with any diluent other than 5% Dextrose Injection.
Do not use any bacteriostatic agent, such as benzyl alcohol.
DOXIL is not a clear solution but a translucent, red liposomal dispersion.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use if a precipitate or foreign matter is present.
Rapid flushing of the infusion line should be avoided.
Caution should be exercised in the handling and preparation of DOXIL.
The use of gloves is required.
If DOXIL comes into contact with skin or mucosa, immediately wash thoroughly with soap and water.
DOXIL should be considered an irritant and precautions should be taken to avoid extravasation. With intravenous administration of DOXIL, extravasation may occur with or without an accompanying stinging or burning sensation, even if blood returns well on aspiration of the infusion needle. If any signs or symptoms of extravasation have occurred, the infusion should be immediately terminated and restarted in another vein. DOXIL must not be given by the intramuscular or subcutaneous route.
DOXIL should be handled and disposed of in a manner consistent with other anticancer drugs. Several guidelines on this subject exist [see References].
DOXIL (doxorubicin HCl liposome injection) is supplied as a sterile, translucent, red liposomal dispersion in 10-mL or 30-mL glass, single use vials.
Each 10-mL vial contains 20 mg doxorubicin HCl at a concentration of 2 mg/mL.
Each 30-mL vial contains 50 mg doxorubicin HCl at a concentration of 2 mg/mL.
Refrigerate unopened vials of DOXIL at 2° -8° C (36° -46° F). Avoid freezing. Prolonged freezing may adversely affect liposomal drug products; however, short-term freezing (less than 1 month) does not appear to have a deleterious effect on DOXIL.
The following packages of six individually cartoned vials are available:
Table 19
| mg in vial | fill volume | vial size | NDC #s |
| 20 mg vial | 10-mL | 10-mL | 17314-9600-1 |
| 50 mg vial | 25-mL | 30-mL | 17314-9600-2 |
Manufactured by: Ben Venue Laboratories, Inc., Bedford, OH 44146. Distributed by: Ortho Biotech Products, LP Raritan, NJ 08869-0670. FDA revision date: 6/10/2008
REFERENCES
1. NIOSH Alert: Preventing occupational exposures to antineoplastic and other hazardous drugs in healthcare settings. 2004. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No. 2004-165.
2. OSHA Technical Manual, TED 1-0.15A, Section VI: Chapter 2. Controlling Occupational Exposure to Hazardous Drugs. OSHA, 1999. http://www.osha.gov/dts/osta/otm/otm_vi/otm_vi_2.html
3. NIH [2002]. 1999 recommendations for the safe handling of cytotoxic drugs. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, NIH Publication No. 92-2621.
4. American Society of Health-System Pharmacists. (2006) ASHP Guidelines on Handling Hazardous Drugs.
5. Polovich, M., White, J. M., & Kelleher, L.O. (eds.) 2005. Chemotherapy and biotherapy guidelines and recommendations for practice (2nd. ed.) Pittsburgh, PA: Oncology Nursing Society.
Last updated on RxList: 7/8/2008
The following adverse reactions are discussed in more detail in other sections of the labeling.
The most common adverse reactions observed with DOXIL are asthenia, fatigue, fever, nausea, stomatitis, vomiting, diarrhea, constipation, anorexia, hand-foot syndrome, rash and neutropenia, thrombocytopenia and anemia.
The most common serious adverse reactions observed with DOXIL are described in Section 6.2.
The safety data described below reflect exposure to DOXIL in 1310 patients including: 239 patients with ovarian cancer, 753 patients with AIDS-related Kaposi's sarcoma and 318 patients with multiple myeloma [see ADVERSE REACTIONS in Clinical Trials].
Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed cannot be directly compared to rates on other clinical trials and may not reflect the rates observed in clinical practice.
The following tables present adverse reactions from clinical trials of DOXIL in ovarian cancer and AIDS-Related Kaposi's sarcoma.
The safety data described below are from 239 patients with ovarian cancer treated with DOXIL (doxorubicin HCl liposome injection) at 50 mg/m² once every 4 weeks for a minimum of 4 courses in a randomized, multicenter, open-label study. In this study, patients received DOXIL for a median number of 98.0 days (range 1-785 days). The population studied was 27-87 years of age, 91% Caucasian, 6% Black and 3% Hispanic and other.
Table 6 presents the hematologic adverse reactions from the randomized study of DOXIL compared to topotecan.
Table 6: Ovarian Cancer Randomized Study Hematology Data
Reported in Patients With Ovarian Cancer
| DOXIL Patients (n = 239) |
Topotecan Patients (n = 235) |
|
| Neutropenia | ||
| 500 - < 1000/mm³ | 19 (7.9%) | 33 (14.0%) |
| < 500/mm³ | 10 (4.2%) | 146 (62.1%) |
| Anemia | ||
| 6.5 - < 8 g/dL | 13 (5.4%) | 59 (25.1%) |
| < 6.5 g/dL | 1 (0.4%) | 10 (4.3%) |
| Thrombocytopenia | ||
| 10,000 - < 50,000/mm³ | 3 (1.3%) | 40 (17.0%) |
| < 10,000/mm³ | 0 (0.0%) | 40 (17.0%) |
Table 7 presents a comparative profile of the non-hematologic adverse reactions from the randomized study of DOXIL compared to topotecan.
Table 7: Ovarian Cancer Randomized Study
| Non-Hematologic Adverse Reaction 10% or Greater |
DOXIL (%) treated (n =239) |
Topotecan (%) treated (n=235) |
||
| All grades | Grades 3-4 | All grades | Grades 3-4 | |
| Body as a Whole | ||||
| Asthenia | 40.2 | 7.1 | 51.5 | 8.1 |
| Fever | 21.3 | 0.8 | 30.6 | 5.5 |
| Mucous Membrane | 14.2 | 3.8 | 3.4 | 0 |
| Disorder | ||||
| Back Pain | 11.7 | 1.7 | 10.2 | 0.9 |
| Infection | 11.7 | 2.1 | 6.4 | 0.9 |
| Headache | 10.5 | 0.8 | 14.9 | 0 |
| Digestive | ||||
| Nausea | 46.0 | 5.4 | 63.0 | 8.1 |
| Stomatitis | 41.4 | 8.3 | 15.3 | 0.4 |
| Vomiting | 32.6 | 7.9 | 43.8 | 9.8 |
| Diarrhea | 20.9 | 2.5 | 34.9 | 4.2 |
| Anorexia | 20.1 | 2.5 | 21.7 | 1.3 |
| Dyspepsia | 12.1 | 0.8 | 14.0 | 0 |
| Nervous | ||||
| Dizziness | 4.2 | 0 | 10.2 | 0 |
| Respiratory | ||||
| Pharyngitis | 15.9 | 0 | 17.9 | 0.4 |
| Dyspnea | 15.1 | 4.1 | 23.4 | 4.3 |
| Cough increased | 9.6 | 0 | 11.5 | 0 |
| Skin and Appendages | ||||
| Hand-foot syndrome | 50.6 | 23.8 | 0.9 | 0 |
| Rash | 28.5 | 4.2 | 12.3 | 0.4 |
| Alopecia | 19.2 | N/A | 52.3 | N/A |
The following additional adverse reactions (not in table) were observed in patients with ovarian cancer with doses administered every four weeks.
Incidence 1% to 10%
Cardiovascular: vasodilation, tachycardia, deep thrombophlebitis, hypotension, cardiac arrest.
Digestive: oral moniliasis, mouth ulceration, esophagitis, dysphagia, rectal bleeding, ileus.
Hemic and Lymphatic: ecchymosis.
Metabolic and Nutritional: dehydration, weight loss, hyperbilirubinemia, hypokalemia, hypercalcemia, hyponatremia.
Nervous: somnolence, dizziness, depression.
Respiratory: rhinitis, pneumonia, sinusitis, epistaxis.
Skin and Appendages: pruritus, skin discoloration, vesiculobullous rash, maculopapular rash, exfoliative dermatitis, herpes zoster, dry skin, herpes simplex, fungal dermatitis, furunculosis, acne.
Special Senses: conjunctivitis, taste perversion, dry eyes.
Urinary: urinary tract infection, hematuria, vaginal moniliasis.
The safety data below is based on the experience reported in 753 patients with AIDSrelated Kaposi's sarcoma enrolled in four studies. The median age of the population was 38.7 years (range 24-70 years), which was 99% male, 1% female, 88% Caucasian, 6% Hispanic, 4% Black, and 2% Asian/other/unknown. The majority of patients were treated with 20 mg/m² of DOXIL every two to three weeks. The median time on study was 127 days and ranged from 1 to 811 days. The median cumulative dose was 120 mg/m² and ranged from 3.3 to 798.6 mg/m². Twenty-six patients (3.0%) received cumulative doses of greater than 450 mg/m².
Of these 753 patients, 61.2% were considered poor risk for KS tumor burden, 91.5% poor for immune system, and 46.9% for systemic illness; 36.2% were poor risk for all three categories. Patients' median CD4 count was 21.0 cells/mm³, with 50.8% of patients having less than 50 cells/mm³. The mean absolute neutrophil count at study entry was approximately 3,000 cells/mm³.
Patients received a variety of potentially myelotoxic drugs in combination with DOXIL. Of the 693 patients with concomitant medication information, 58.7% were on one or more antiretroviral medications; 34.9% patients were on zidovudine (AZT), 20.8% on didanosine (ddI), 16.5% on zalcitabine (ddC), and 9.5% on stavudine (D4T). A total of 85.1% patients were on PCP prophylaxis, most (54.4%) on sulfamethoxazole/trimethoprim. Eighty-five percent of patients were receiving antifungal medications, primarily fluconazole (75.8%). Seventy-two percent of patients were receiving antivirals, 56.3% acyclovir, 29% ganciclovir, and 16% foscarnet. In addition, 47.8% patients received colony-stimulating factors (sargramostim/filgrastim) sometime during their course of treatment.
Adverse reactions led to discontinuation of treatment in 5% of patients with AIDS related Kaposi's sarcoma. Those that did so included bone marrow suppression, cardiac adverse reactions, infusion-related reactions, toxoplasmosis, HFS, pneumonia, cough/dyspnea, fatigue, optic neuritis, progression of a non-KS tumor, allergy to penicillin, and unspecified reasons.
Table 8: Hematology Data Reported in Patients With AIDS-Related
Kaposi's Sarcoma
| Patients With Refractory or Intolerant AIDS-Related Kaposi's (n = 74) |
Total Patients With AIDS-Related (n = 720) |
|||
| Neutropenia | ||||
| < 1000/mm³ | 34 | (45.9%) | 352 | (48.9%) |
| < 500/mm³ | 8 | (10.8%) | 96 | (13.3%) |
| Anemia | ||||
| < 10 g/dL | 43 | (58.1%) | 399 | (55.4%) |
| < 8 g/dL | 12 | (16.2%) | 131 | (18.2%) |
| Thrombocytopenia | ||||
| < 150,000/mm³ | 45 | (60.8%) | 439 | (60.9%) |
| < 25,000/mm³ | 1 | (1.4%) | 30 | (4.2%) |
Table 9: Probably and Possibly Drug-Related Non-Hematologic
Adverse Reactions Reported in ≥ 5% of Patients With AIDS-Related Kaposi's
| Adverse Reactions | Patients With Refractory or IntolerantAIDS-Related Kaposi's (n = 77) |
Total Patients With AIDS-Related (n = 705) |
||
| Nausea | 14 | (18.2%) | 119 | (16.9%) |
| Asthenia | 5 | (6.5%) | 70 | (9.9%) |
| Fever | 6 | (7.8%) | 64 | (9.1%) |
| Alopecia | 7 | (9.1%) | 63 | (8.9%) |
| Alkaline Phosphatase Increase | 1 | (1.3%) | 55 | (7.8%) |
| Vomiting | 6 | (7.8%) | 55 | (7.8%) |
| Diarrhea | 4 | (5.2%) | 55 | (7.8%) |
| Stomatitis | 4 | (5.2%) | 48 | (6.8%) |
| Oral Moniliasis | 1 | (1.3%) | 39 | (5.5%) |
The following additional (not in table) adverse reactions were observed in patients with AIDS-related Kaposi's sarcoma.
Incidence 1% to 5%
Body as a Whole: headache, back pain, infection, allergic reaction, chills.
Cardiovascular: chest pain, hypotension, tachycardia.
Cutaneous: herpes simplex, rash, itching.
Digestive: mouth ulceration, anorexia, dysphagia.
Metabolic and Nutritional: SGPT increase, weight loss, hyperbilirubinemia.
Other: dyspnea, pneumonia, dizziness, somnolence.
Incidence Less Than 1%
Body As A Whole: sepsis, moniliasis, cryptococcosis.
Cardiovascular: thrombophlebitis, cardiomyopathy, palpitation, bundle branch block, congestive heart failure, heart arrest, thrombosis, ventricular arrhythmia.
Digestive: hepatitis.
Metabolic and Nutritional Disorders: dehydration
Respiratory: cough increase, pharyngitis.
Skin and Appendages: maculopapular rash, herpes zoster.
Special Senses: taste perversion, conjunctivitis.
The safety data below are from 318 patients treated with DOXIL (30 mg/m² as a 1-hr i.v. infusion) administered on day 4 following bortezomib (1.3 mg/m² i.v. bolus on days 1, 4, 8 and 11) every three weeks, in a randomized, open-label, multicenter study. In this study, patients in the DOXIL + bortezomib combination group were treated for a median number of 138 days (range 21-410 days). The population was 28-85 years of age, 58% male, 42% female, 90% Caucasian, 6% Black, and 4% Asian and other. Table 10 lists adverse reactions reported in 10% or more of patients treated with DOXIL in combination with bortezomib for multiple myeloma.
Table 10. Frequency of treatment emergent adverse reactions
reported in ≥ 10% patients treated for multiple myeloma with DOXIL in combination
with bortezomib, by Severity, Body System, and MedDRA Terminology.
| Adverse Reaction | DOXIL + bortezomib (n=318) |
Bortezomib (n=318) |
||||
| Any (%) | Grade 3 | Grade 4 | Any (%) | Grade 3 | Grade 4 | |
| Blood and lymphatic system disorders | ||||||
| Neutropenia | 36 | 22 | 10 | 22 | 11 | 5 |
| Thrombocytopenia | 33 | 11 | 13 | 28 | 9 | 8 |
| Anemia | 25 | 7 | 2 | 21 | 8 | 2 |
| General disorders and administration site conditions | ||||||
| Fatigue | 36 | 6 | 1 | 28 | 3 | 0 |
| Pyrexia | 31 | 1 | 0 | 22 | 1 | 0 |
| Asthenia | 22 | 6 | 0 | 18 | 4 | 0 |
| Gastrointestinal disorders | ||||||
| Nausea | 48 | 3 | 0 | 40 | 1 | 0 |
| Diarrhea | 46 | 7 | 0 | 39 | 5 | 0 |
| Vomiting | 32 | 4 | 0 | 22 | 1 | 0 |
| Constipation | 31 | 1 | 0 | 31 | 1 | 0 |
| Mucositis/Stomatitis | 20 | 2 | 0 | 5 | < 1 | 0 |
| Abdominal pain | 11 | 1 | 0 | 8 | 1 | 0 |
| Infections and infestations | ||||||
| Herpes zoster | 11 | 2 | 0 | 9 | 2 | 0 |
| Herpes simplex | 10 | 0 | 0 | 6 | 1 | 0 |
| Investigations | ||||||
| Weight decreased | 12 | 0 | 0 | 4 | 0 | 0 |
| Metabolism and Nutritional disorders | ||||||
| Anorexia | 19 | 2 | 0 | 14 | < 1 | 0 |
| Nervous system disorders | ||||||
| Peripheral Neuropathy* | 42 | 7 | < 1 | 45 | 10 | 1 |
| Neuralgia | 17 | 3 | 0 | 20 | 4 | 1 |
| Paresthesia/dysesthesia | 13 | < 1 | 0 | 10 | 0 | 0 |
| Respiratory, thoracic and mediastinal disorders | ||||||
| Cough | 18 | 0 | 0 | 12 | 0 | 0 |
| Skin and subcutaneous tissue disorders | ||||||
| Rash** | 22 | 1 | 0 | 18 | 1 | 0 |
| Hand-foot syndrome | 19 | 6 | 0 | < 1 | 0 | 0 |
| *Peripheral neuropathy includes the following
adverse reactions: peripheral sensory neuropathy, neuropathy peripheral,
polyneuropathy, peripheral motor neuropathy, and neuropathy NOS. **Rash includes the following adverse reactions: rash, rash erythematous, rash macular, rash maculo-papular, rash pruritic, exfoliative rash, and rash generalized. |
||||||
The following additional adverse reactions have been identified during post approval use of DOXIL. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Musculoskeletal and Connective Tissue Disorders: rare cases of muscle spasms.
Respiratory, Thoracic and Mediastinal Disorders: rare cases of pulmonary embolism (in some cases fatal).
Hematologic disorders: Secondary acute myelogenous leukemia with and without fatal outcome has been reported in patients whose treatment included DOXIL.
Skin and subcutaneous tissue disorders: rare cases of erythema multiforme, Stevens- Johnson syndrome and toxic epidermal necrolysis have been reported.
No formal drug interaction studies have been conducted with DOXIL. DOXIL may interact with drugs known to interact with the conventional formulation of doxorubicin HCl.
Last updated on RxList: 7/8/2008
Special attention must be given to the risk of myocardial damage from cumulative doses of doxorubicin HCl. Acute left ventricular failure may occur with doxorubicin, particularly in patients who have received a total cumulative dosage of doxorubicin exceeding the currently recommended limit of 550 mg/m². Lower (400 mg/m²) doses appear to cause heart failure in patients who have received radiotherapy to the mediastinal area or concomitant therapy with other potentially cardiotoxic agents such as cyclophosphamide.
Prior use of other anthracyclines or anthracenodiones should be included in calculations of total cumulative dosage. Congestive heart failure or cardiomyopathy may be encountered after discontinuation of anthracycline therapy. Patients with a history of cardiovascular disease should be administered DOXIL only when the potential benefit of treatment outweighs the risk.
Cardiac function should be carefully monitored in patients treated with DOXIL. The most definitive test for anthracycline myocardial injury is endomyocardial biopsy. Other methods, such as echocardiography or multigated radionuclide scans, have been used to monitor cardiac function during anthracycline therapy. Any of these methods should be employed to monitor potential cardiac toxicity in patients treated with DOXIL. If these test results indicate possible cardiac injury associated with DOXIL therapy, the benefit of continued therapy must be carefully weighed against the risk of myocardial injury.
In a clinical study in patients with advanced breast cancer, 250 patients received DOXIL at starting dose of 50 mg/m² every 4 weeks. At all cumulative anthracycline doses between 450-500 mg/m², or between 500-550 mg/m², the risk of cardiac toxicity for patients treated with DOXIL was 11%. In this study, cardiotoxicity was defined as a decrease of > 20% from baseline if the resting left ventricular ejection fraction (LVEF) remained in the normal range, or a decrease of > 10% if the resting LVEF became abnormal (less than the institutional lower limit of normal). The data on left ventricular ejection fraction (LVEF) defined cardiotoxicity and congestive heart failure (CHF) are in the table below.
Table 5: Number of Patients With Advanced Breast Cancer
| DOXIL (n=250) | |
| Patients who Developed Cardiotoxicity (LVEF Defined) | 10 |
| Cardiotoxicity (With Signs & Symptoms of CHF) | 0 |
| Cardiotoxicity (no Signs & Symptoms of CHF) | 10 |
| Patients With Signs and Symptoms of CHF Only | 2 |
In the randomized multiple myeloma study, the incidence of heart failure events (ventricular dysfunction, cardiac failure, right ventricular failure, congestive cardiac failure, chronic cardiac failure, acute pulmonary edema and pulmonary edema) was similar in the DOXIL+bortezomib group and the bortezomib monotherapy group, 3% in each group. LVEF decrease was defined as an absolute decrease of ≥ 15% over baseline or a ≥ 5% decrease below the institutional lower limit of normal. Based on this definition, 25 patients in the bortezomib arm (8%) and 42 patients in the DOXIL + bortezomib arm (13%) experienced a reduction in LVEF.
Acute infusion-related reactions were reported in 7.1% of patients treated with DOXIL in the randomized ovarian cancer study. These reactions were characterized by one or more of the following symptoms: flushing, shortness of breath, facial swelling, headache, chills, chest pain, back pain, tightness in the chest and throat, fever, tachycardia, pruritus, rash, cyanosis, syncope, bronchospasm, asthma, apnea, and hypotension. In most patients, these reactions resolve over the course of several hours to a day once the infusion is terminated. In some patients, the reaction resolved when the rate of infusion was slowed. In this study, two patients treated with DOXIL (0.8%) discontinued due to infusion-related reactions. In clinical studies, six patients with AIDS-related Kaposi's sarcoma (0.9%) and 13 (1.7%) solid tumor patients discontinued DOXIL therapy because of infusion-related reactions.
Serious and sometimes life-threatening or fatal allergic/anaphylactoid-like infusion reactions have been reported. Medications to treat such reactions, as well as emergency equipment, should be available for immediate use.
The majority of infusion-related events occurred during the first infusion. Similar reactions have not been reported with conventional doxorubicin and they presumably represent a reaction to the DOXIL liposomes or one of its surface components.
The initial rate of infusion should be 1 mg/min to help minimize the risk of infusion reactions [see DOSAGE AND ADMINISTRATION].
Because of the potential for bone marrow suppression, careful hematologic monitoring is required during use of DOXIL, including white blood cell, neutrophil, platelet counts, and Hgb/Hct. With the recommended dosage schedule, leukopenia is usually transient. Hematologic toxicity may require dose reduction or delay or suspension of DOXIL therapy. Persistent severe myelosuppression may result in superinfection, neutropenic fever, or hemorrhage. Development of sepsis in the setting of neutropenia has resulted in discontinuation of treatment and, in rare cases, death.
DOXIL may potentiate the toxicity of other anticancer therapies. In particular, hematologic toxicity may be more severe when DOXIL is administered in combination with other agents that cause bone marrow suppression.
In patients with relapsed ovarian cancer, myelosuppression was generally moderate and reversible. In the three single-arm studies, anemia was the most common hematologic adverse reaction (52.6%), followed by leukopenia (WBC < 4,000 mm³; 42.2%), thrombocytopenia (24.2%), and neutropenia (ANC < 1,000; 19.0%). In the randomized study, anemia was the most common hematologic adverse reaction (40.2%), followed by leukopenia (WBC < 4,000 mm³; 36.8%), neutropenia (ANC < 1,000; 35.1%), and thrombocytopenia (13.0%) [see ADVERSE REACTIONS].
In patients with relapsed ovarian cancer, 4.6% received G-CSF (or GM-CSF) to support their blood counts [see DOSAGE AND ADMINISTRATIONS].
For patients with AIDS-related Kaposi's sarcoma who often present with baseline myelosuppression due to such factors as their HIV disease or concomitant medications, myelosuppression appears to be the dose-limiting adverse reaction at the recommended dose of 20 mg/m² [see ADVERSE REACTIONS]. Leukopenia is the most common adverse reaction experienced in this population; anemia and thrombocytopenia can also be expected. Sepsis occurred in 5% of patients; for 0.7% of patients the event was considered possibly or probably related to DOXIL. Eleven patients (1.6%) discontinued study because of bone marrow suppression or neutropenia.
Table 10 presents data on myelosuppression in patients with multiple myeloma receiving DOXIL and bortezomib in combination [see ADVERSE REACTIONS].
In the randomized ovarian cancer study, 50.6% of patients treated with DOXIL at 50 mg/m² every 4 weeks experienced HFS (developed palmar-plantar skin eruptions characterized by swelling, pain, erythema and, for some patients, desquamation of the skin on the hands and the feet), with 23.8% of the patients reporting HFS Grade 3 or 4 events. Ten subjects (4.2%) discontinued treatment due to HFS or other skin toxicity. HFS toxicity grades are described above [see definitions of HFS grades in DOSAGE AND ADMINISTRATION].
Among 705 patients with AIDS-related Kaposi's sarcoma treated with DOXIL at 20 mg/m² every 2 weeks, 24 (3.4%) developed HFS, with 3 (0.9%) discontinuing.
In the randomized multiple myeloma study, 19% of patients treated with DOXIL at 30 mg/m² every three weeks experienced HFS.
HFS was generally observed after 2 or 3 cycles of treatment but may occur earlier. In most patients the reaction is mild and resolves in one to two weeks so that prolonged delay of therapy need not occur. However, dose modification may be required to manage HFS [see DOSAGE AND ADMINISTRATION]. The reaction can be severe and debilitating in some patients and may require discontinuation of treatment.
Recall reaction has occurred with DOXIL administration after radiotherapy.
DOXIL can cause fetal harm when administered to a pregnant woman. There are no adequate and well-controlled studies in pregnant women. If DOXIL is to be used during pregnancy, or if the patient becomes pregnant during therapy, the patient should be apprised of the potential hazard to the fetus. If pregnancy occurs in the first few months following treatment with DOXIL, the prolonged half-life of the drug must be considered. Women of childbearing potential should be advised to avoid pregnancy during treatment with Doxil. [see Use in Specific Populations].
The doxorubicin in DOXIL may potentiate the toxicity of other anticancer therapies. Exacerbation of cyclophosphamide-induced hemorrhagic cystitis and enhancement of the hepatotoxicity of 6-mercaptopurine have been reported with the conventional formulation of doxorubicin HCl. Radiation-induced toxicity to the myocardium, mucosae, skin, and liver have been reported to be increased by the administration of doxorubicin HCl.
Complete blood counts, including platelet counts, should be obtained frequently and at a minimum prior to each dose of DOXIL [see WARNINGS and PRECAUTIONS].
Although no studies have been conducted with DOXIL, doxorubicin HCl and related compounds have been shown to have mutagenic and carcinogenic properties when tested in experimental models.
STEALTH® liposomes without drug were negative when tested in Ames, mouse lymphoma and chromosomal aberration assays in vitro, and mammalian micronucleus assay in vivo.
The possible adverse effects on fertility in males and females in humans or experimental animals have not been adequately evaluated. However, DOXIL resulted in mild to moderate ovarian and testicular atrophy in mice after a single dose of 36 mg/kg (about twice the 50 mg/m² human dose on a mg/m² basis). Decreased testicular weights and hypospermia were present in rats after repeat doses ≥ 0.25 mg/kg/day (about one thirtieth the 50 mg/m² human dose on a mg/m² basis), and diffuse degeneration of the seminiferous tubules and a marked decrease in spermatogenesis were observed in dogs after repeat doses of 1 mg/kg/day (about one half the 50 mg/m² human dose on a mg/m² basis).
[see WARNINGS and PRECAUTIONS].
DOXIL is embryotoxic at doses of 1 mg/kg/day in rats and is embryotoxic and abortifacient at 0.5 mg/kg/day in rabbits (both doses are about one-eighth the 50 mg/m² human dose on a mg/m² basis). Embryotoxicity was characterized by increased embryo-fetal deaths and reduced live litter sizes.
It is not known whether this drug is excreted in human milk. Because many drugs, including anthracyclines, are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from DOXIL, mothers should discontinue nursing prior to taking this drug.
The safety and effectiveness of DOXIL in pediatric patients have not been established.
Of the patients treated with DOXIL in the randomized ovarian cancer study, 34.7% (n=83) were 65 years of age or older while 7.9% (n=19) were 75 years of age or older. Of the 318 patients treated with DOXIL in combination with bortezomib for multiple myeloma, 37% were 65 years of age or older and 8% were 75 years of age or older. No overall differences in safety or efficacy were observed between these patients and younger patients.
The pharmacokinetics of DOXIL has not been adequately evaluated in patients with hepatic impairment. Doxorubicin is eliminated in large part by the liver. Thus, DOXIL dosage should be reduced in patients with impaired hepatic function [see DOSAGE AND ADMINISTRATION].
Prior to DOXIL administration, evaluation of hepatic function is recommended using conventional clinical laboratory tests such as SGOT, SGPT, alkaline phosphatase, and bilirubin [see DOSAGE AND ADMINISTRATION].
Last updated on RxList: 7/8/2008
Acute overdosage with doxorubicin HCl causes increases in mucositis, leucopenia, and thrombocytopenia.
Treatment of acute overdosage consists of treatment of the severely myelosuppressed patient with hospitalization, antibiotics, platelet and granulocyte transfusions, and symptomatic treatment of mucositis.
DOXIL (doxorubicin HCl liposome injection) is contraindicated in patients who have a history of hypersensitivity reactions to a conventional formulation of doxorubicin HCl or the components of DOXIL [see WARNINGS and PRECAUTIONS].
DOXIL is contraindicated in nursing mothers [see Use in Specific Populations].
Last updated on RxList: 7/8/2008
The active ingredient of DOXIL is doxorubicin HCl. The mechanism of action of doxorubicin HCl is thought to be related to its ability to bind DNA and inhibit nucleic acid synthesis. Cell structure studies have demonstrated rapid cell penetration and perinuclear chromatin binding, rapid inhibition of mitotic activity and nucleic acid synthesis, and induction of mutagenesis and chromosomal aberrations.
DOXIL is doxorubicin HCl encapsulated in long-circulating STEALTH® liposomes. Liposomes are microscopic vesicles composed of a phospholipid bilayer that are capable of encapsulating active drugs. The STEALTH® liposomes of DOXIL are formulated with surface-bound methoxypolyethylene glycol (MPEG), a process often referred to as pegylation, to protect liposomes from detection by the mononuclear phagocyte system (MPS) and to increase blood circulation time.
Representation of a STEALTH® liposome:
 |
STEALTH® liposomes have a half-life of approximately 55 hours in humans. They are stable in blood, and direct measurement of liposomal doxorubicin shows that at least 90% of the drug (the assay used cannot quantify less than 5-10% free doxorubicin) remains liposome-encapsulated during circulation.
It is hypothesized that because of their small size (ca. 100 nm) and persistence in the circulation, the pegylated DOXIL liposomes are able to penetrate the altered and often compromised vasculature of tumors. This hypothesis is supported by studies using colloidal gold-containing STEALTH® liposomes, which can be visualized microscopically. Evidence of penetration of STEALTH® liposomes from blood vessels and their entry and accumulation in tumors has been seen in mice with C-26 colon carcinoma tumors and in transgenic mice with Kaposi's sarcoma-like lesions. Once the STEALTH® liposomes distribute to the tissue compartment, the encapsulated doxorubicin HCl becomes available. The exact mechanism of release is not understood.
The plasma pharmacokinetics of DOXIL were evaluated in 42 patients with AIDS-related Kaposi's sarcoma (KS) who received single doses of 10 or 20 mg/m² administered by a 30-minute infusion. Twenty-three of these patients received single doses of both 10 and 20 mg/m² with a 3-week wash-out period between doses. The pharmacokinetic parameter values of DOXIL, given for total doxorubicin (mostly liposomally bound), are presented in Table 11.
Table 11: Pharmacokinetic Parameters of DOXIL in Patients
With AIDS-Related Kaposi's Sarcoma
| Dose | ||
| Parameter (units) | 10 mg/m² | 20 mg/m² |
| Peak Plasma Concentration ( μ g/mL) | 4.12 ± 0.215 | 8.34 ± 0.49 |
| Plasma Clearance (L/h/m²) | 0.056 ± 0.01 | 0.041 ± 0.004 |
| Steady State Volume of Distribution (L/m²) | 2.83 ± 0.145 | 2.72 ± 0.120 |
| AUC (μ g/mL•h) | 277 ± 32.9 | 590 ± 58.7 |
| First Phase (λ1) Half-Life (h) | 4.7 ± 1.1 | 5.2 ± 1.4 |
| Second Phase (λ1) Half-Life (h) | 52.3 ± 5.6 | 55.0 ± 4.8 |
| N = 23 Mean ± Standard Error |
||
DOXIL displayed linear pharmacokinetics over the range of 10 to 20 mg/m². Disposition occurred in two phases after DOXIL administration, with a relatively short first phase (~ 5 hours) and a prolonged second phase (~ 55 hours) that accounted for the majority of the area under the curve (AUC).
The pharmacokinetics of DOXIL at a 50 mg/m² dose is reported to be nonlinear. At this dose, the elimination half-life of DOXIL is expected to be longer and the clearance lower compared to a 20 mg/m² dose. The exposure (AUC) is thus expected to be more than proportional at a 50 mg/m² dose when compared with the lower doses.
In contrast to the pharmacokinetics of doxorubicin, which displays a large volume of distribution, ranging from 700 to 1100 L/m², the small steady state volume of distribution of DOXIL shows that DOXIL is confined mostly to the vascular fluid volume. Plasma protein binding of DOXIL has not been determined; the plasma protein binding of doxorubicin is approximately 70%.
Doxorubicinol, the major metabolite of doxorubicin, was detected at very low levels (range: of 0.8 to 26.2 ng/mL) in the plasma of patients who received 10 or 20 mg/m² DOXIL.
The plasma clearance of DOXIL was slow, with a mean clearance value of 0.041 L/h/m² at a dose of 20 mg/m². This is in contrast to doxorubicin, which displays a plasma clearance value ranging from 24 to 35 L/h/m².
Because of its slower clearance, the AUC of DOXIL, primarily representing the circulation of liposome-encapsulated doxorubicin, is approximately two to three orders of magnitude larger than the AUC for a similar dose of conventional doxorubicin HCl as reported in the literature.
The pharmacokinetics of DOXIL have not been separately evaluated in women, in members of different ethnic groups, or in individuals with renal or hepatic insufficiency.
Drug-drug interactions between DOXIL and other drugs, including antiviral agents, have not been adequately evaluated in patients with ovarian cancer, AIDS-related Kaposi's sarcoma or multiple myeloma.
Kaposi's sarcoma lesions and normal skin biopsies were obtained at 48 and 96 hours post infusion of 20 mg/m² DOXIL in 11 patients. The concentration of DOXIL in KS lesions was a median of 19 (range, 3-53) times higher than in normal skin at 48 hours post treatment; however, this was not corrected for likely differences in blood content between KS lesions and normal skin. The corrected ratio may lie between 1 and 22 times. Thus, higher concentrations of DOXIL are delivered to KS lesions than to normal skin.
DOXIL (doxorubicin HCl liposome injection) was studied in three open-label, single-arm, clinical studies of 176 patients with metastatic ovarian cancer. One hundred forty-five (145) of these patients were refractory to both paclitaxel- and platinum-based chemotherapy regimens. Refractory ovarian cancer is defined as disease progression while on treatment, or relapse within 6 months of completing treatment. Patients in these studies received DOXIL at 50 mg/m² infused over one hour every 3 or 4 weeks for 3-6 cycles or longer in the absence of dose-limiting toxicity or progression of disease.
The baseline demographics and clinical characteristics of the patients with refractory ovarian cancer are provided in Table 12 below.
Table 12: Patient Demographics for Patients With Refractory
Ovarian Cancer From Single Arm Ovarian Cancer Studies
| Study 1 (U.S.) (n = 27) |
Study 2 (U.S.) (n = 82) |
Study 3 (non-U.S.) (n = 36) |
|
| Age at Diagnosis (Years) | |||
| Median | 64 | 61.5 | 51.5 |
| Range | 46 - 75 | 34 - 85 | 22 - 80 |
| Drug-Free Interval (Months) | |||
| Median | 1.8 | 1.7 | 2.6 |
| Range | 0.5 - 15.6 | 0.6 - 7.0 | 0.7 - 15.2 |
| Sum of Lesions at Baseline (cm²) | |||
| Median | 25 | 18.3 | 32.4 |
| Range | 1.2 - 230.0 | 1.3 - 285.0 | 0.3 - 114.0 |
| FIGO Staging | |||
| I | 1 (3.7%) | 3 (3.7%) | 4 (11.1%) |
| II | 3 (11.1%) | 3 (3.7%) | 1 (2.8%) |
| III | 15 (55.6%) | 60 (73.2%) | 24 (66.7%) |
| IV | 8 (29.6%) | 16 (19.5%) | 6 (16.7%) |
| Not Specified | 1 (2.8%) | ||
| CA-125 at Baseline | |||
| Median | 123.5 | 199.0 | 1004.5 |
| Range | 20 - 14,012 | 7 - 46,594 | 20 - 12,089 |
| Number of Prior Chemotherapy Regimens | |||
| 1 | 7 (25.9%) | 13 (15.9%) | 9 (25.0%) |
| 2 | 11 (40.7%) | 44 (53.7%) | 19 (52.8%) |
| 3 | 6 (22.2%) | 25 (30.5%) | 8 (22.8%) |
| 4 | 3 (11.1%) | ||
The primary efficacy parameter was response rate for the population of patients refractory to both paclitaxel- and a platinum-containing regimen. Assessment of response was based on Southwest Oncology Group (SWOG) criteria, and required confirmation four weeks after the initial observation. Secondary efficacy parameters were time to response, duration of response, and time to progression.
The response rates for the individual single arm studies are given in Table 13 below.
Table 13: Response Rates in Patients With Refractory Ovarian
Cancer From Single Arm Ovarian Cancer Studies
| Study 1 (U.S.) | Study 2 (U.S.) | Study 3 (non-U.S.) | |
| Response Rate | 22.2% (6/27) | 17.1% (14/82) | 0% (0/36) |
| 95% Confidence Interval | 8.6% - 42.3% | 9.7% - 27.0% | 0.0% - 9.7% |
When the data from the single arm studies are combined, the response rate for all patients refractory to paclitaxel and platinum agents was 13.8% (20/145) (95% CI 8.1% to 19.3%). The median time to progression was 15.9 weeks, the median time to response was 17.6 weeks, and the duration of response was 39.4 weeks.
DOXIL (doxorubicin HCl liposome injection) was also studied in a randomized, multicenter, open-label, study in 474 patients with epithelial ovarian cancer after platinum-based chemotherapy. Patients in this study received an initial dose of either DOXIL 50 mg/m² infused over one hour every 4 weeks or topotecan 1.5 mg/m² infused daily for 5 consecutive days every 3 weeks. Patients were stratified according to platinum sensitivity and the presence of bulky disease (presence of tumor mass greater than 5 cm in size). Platinum sensitivity is defined by response to initial platinum-based therapy and a progression-free interval of greater than 6 months off treatment. The primary efficacy endpoint for this study was time to progression (TTP). Other efficacy endpoints included overall survival and objective response rate.
The baseline patient demographic and clinical characteristics are provided in Table 14 below.
Table 14: Ovarian Cancer Randomized Study Baseline Demographic
and Clinical Characteristics
| DOXIL (n = 239) |
Topotecan (n = 235) |
|
| Age at Diagnosis (Years) | ||
| Median | 60.0 | 60.0 |
| Range | 27 - 87 | 25 - 85 |
| Drug-Free Interval (Months) | ||
| Median | 7.0 | 6.7 |
| Range | 0.9 - 82.1 | 0.5 - 109.6 |
| FIGO Staging | ||
| I | 11 (4.6%) | 15 (6.4%) |
| II | 13 (5.4%) | 8 (3.4%) |
| III | 175 (73.2%) | 164 (69.8%) |
| IV | 40 (16.7%) | 48 (20.4%) |
| Platinum Sensitivity | ||
| Sensitive | 109 (45.6%) | 110 (46.8%) |
| Refractory | 130 (54.4%) | 125 (53.2%) |
| Bulky Disease | ||
| Present | 108 (45.2%) | 105 (44.7%) |
| Absent | 131 (54.8%) | 130 (55.3%) |
Study results are provided in Table 15.
There was no statistically significant difference in TTP between the two treatment arms.
Table 15: Results of Efficacy Analysesa
| Protocol Defined ITT Population | ||
| DOXIL (n = 239) |
Topotecan (n = 235) |
|
| TTP (Protocol Specified Primary Endpoint) | ||
| Median (Months)b | 4.1 | 4.2 |
| p-valuec | 0.617 | |
| Hazard Ratiod | 0.955 | |
| 95% CI for Hazard Ratio | (0.762,1.196) | |
| Overall Survival | ||
| Median (Months) b | 14.4 | 13.7 |
| p-value* | 0.05 | |
| Hazard Ratiod | 0.822 | |
| 95% CI for Hazard Ratio | (0.676,1.000) | |
| Response Rate | ||
| Overall Response n (%) | 47 (19.7) | 40 (17.0) |
| Complete Response n (%) | 9 (3.8) | 11 (4.7) |
| Partial Response n (%) | 38 (15.9) | 29 (12.3) |
| Median Duration of Response (Months) b | 6.9 | 5.9 |
| aAnalysis based on investigators'
strata for protocol defined ITT population. b Kaplan-Meier estimates. cp-value is based on the stratified log-rank test. d Hazard ratio is based on Cox proportional-hazard model with the treatment as single independent variable. A hazard ratio less than 1 indicates an advantage for DOXIL. * p-value not adjusted for multiple comparisons. |
||
DOXIL was studied in an open-label, single-arm, multicenter study utilizing DOXIL at 20 mg/m² by intravenous infusion every three weeks, generally until progression or intolerance occurred. In an interim analysis, the treatment history of 383 patients was reviewed, and a cohort of 77 patients was retrospectively identified as having disease progression on prior systemic combination chemotherapy (at least 2 cycles of a regimen containing at least two of three treatments: bleomycin, vincristine or vinblastine, or doxorubicin) or as being intolerant to such therapy. Forty-nine of the 77 (64%) patients had received prior doxorubicin HCl.
These 77 patients were predominantly Caucasian, homosexual males with a median CD4 count of 10 cells/mm³. Their age ranged from 24 to 54 years, with a mean age of 38 years. Using the ACTG staging criteria, 78% of the patients were at poor risk for tumor burden, 96% at poor risk for immune system, and 58% at poor risk for systemic illness at baseline. Their mean Karnofsky status score was 74%. All 77 patients had cutaneous or subcutaneous lesions, 40% also had oral lesions, 26% pulmonary lesions, and 14% of patients had lesions of the stomach/intestine.
The majority of these patients had disease progression on prior systemic combination chemotherapy.
The median time on study for these 77 patients was 155 days and ranged from 1 to 456 days. The median cumulative dose was 154 mg/m² and ranged from 20 to 620 mg/m².
Two analyses of tumor response were used to evaluate the effectiveness of DOXIL: one analysis based on investigator assessment of changes in lesions over the entire body, and one analysis based on changes in indicator lesions.
Investigator response was based on modified ACTG criteria. Partial response was defined as no new lesions, sites of disease, or worsening edema; flattening of ≥ 50% of previously raised lesions or area of indicator lesions decreasing by ≥ 50%; and response lasting at least 21 days with no prior progression.
A retrospectively defined analysis was conducted based on assessment of the response of up to five prospectively identified representative indicator lesions. A partial response was defined as flattening of ≥ 50% of previously raised indicator lesions, or > 50% decrease in the area of indicator lesions and lasting at least 21 days with no prior progression.
Only patients with adequate documentation of baseline status and follow-up assessments were considered evaluable for response. Patients who received concomitant KS treatment during study, who completed local radiotherapy to sites encompassing one or more of the indicator lesions within two months of study entry, who had less than four indicator lesions, or who had less than three raised indicator lesions at baseline (the latter applies solely to indicator lesion assessment) were considered nonevaluable for response. Of the 77 patients who had disease progression on prior systemic combination chemotherapy or who were intolerant to such therapy, 34 were evaluable for investigator assessment and 42 were evaluable for indicator lesion assessment.
Table 16: Response in Patients with Refractorya AIDS-related
Kaposi's Sarcoma
| Investigator Assessment | All Evaluable Patients(n = 34) |
Evaluable Patients Who Received Prior Doxorubicin(n = 20) |
| Responseb | ||
| Partial (PR) | 27% | 30% |
| Stable | 29% | 40% |
| Progression | 44% | 30% |
| Duration of PR (Days) | ||
| Median | 73 | 89 |
| Range | 42+ - 210+ | 42+ - 210+ |
| Time to PR (Days) | ||
| Median | 43 | 53 |
| Range | 15 - 133 | 15 - 109 |
| Investigator Assessment | All Evaluable Patients (n = 34) |
Evaluable Patients Who Received Prior Doxorubicin (n = 20) |
| Responseb | ||
| Partial (PR) | 27% | 30% |
| Stable | 29% | 40% |
| Progression | 44% | 30% |
| Duration of PR (Days) | ||
| Median | 73 | 89 |
| Range | 42+ - 210+ | 42+ - 210+ |
| Time to PR (Days) | ||
| Median | 43 | 53 |
| Range | 15 - 133 | 15 - 109 |
| Indicator Lesion Assessment |
All Evaluable Patients(n = 42) |
Evaluable Patients Who Received Prior Doxorubicin (n = 23) |
| Responseb | ||
| Partial (PR) | 48% | 52% |
| Stable | 26% | 30% |
| Progression | 26% | 17% |
| Duration of PR (Days) | ||
| Median | 71 | 79 |
| Range | 22+ - 210+ | 35 - 210+ |
| Time to PR (Days) | ||
| Median | 22 | 48 |
| Range | 15 - 109 | 15 - 109 |
| a Patients with disease that
progressed on prior combination chemotherapy or who were intolerant to
such therapy. b There were no complete responses in this population. |
||
Retrospective efficacy analyses were performed on two studies that had subsets of patients who received single agent DOXIL and who were on stable antiretroviral therapy for at least 60 days prior to enrollment and at least until a response was demonstrated. In one cooperative group trial that was closed early due to slow accrual, 7 of 17 patients (40%) on stable antiretroviral therapy had a durable response. The median duration was not reached but was longer than 11.6 months. In another trial, 4 of 11 patients (40%) on stable antiretroviral therapy demonstrated durable responses.
The safety and efficacy of DOXIL in combination with bortezomib in the treatment of multiple myeloma were evaluated in a randomized, open label, international multicenter study. This study included 646 patients who have not previously received bortezomib and whose disease progressed during or after at least one prior therapy. Patients were randomized (1:1 ratio) to receive either DOXIL (30 mg/m² as a 1-hr i.v. infusion) administered on day 4 following bortezomib (1.3 mg/m² i.v. bolus on days 1, 4 , 8 and 11) or bortezomib alone (1.3 mg/m² i.v. bolus on days 1, 4 , 8 and 11). Treatment was administered every 3 weeks. Patients were treated for up to 8 cycles until disease progression or the occurrence of unacceptable toxicity. Patients who maintained a response were allowed to receive further treatment. The median number of cycles in each treatment arm was 5 (range 1-18). The baseline demographics and clinical characteristics of the patients with multiple myeloma are provided in Table 17 below.
Table 17: Summary of Baseline Patient and Disease Characteristics
| Patient Characteristics | DOXIL + bortezomib n=324 |
bortezomib n=322 |
| Median age in years (range) | 61 (28, 85) | 62 (34, 88) |
| % Male/female | 58 / 42 | 54 / 46 |
| % Caucasian/Black/other | 90 / 6/ 4 | 94 / 4 / 2% |
| Disease Characteristics | ||
| % with IgG/IgA/Light chain | 57 / 27 / 12 | 62 / 24 /11 |
| % β2-microglobulin group | ||
| ≤ 2.5 mg/L | 14 | 14 |
| > 2.5 mg/L and ≤ 5.5 mg/L | 56 | 55 |
| > 5.5 mg/L | 30 | 31 |
| Serum M-protein (g/dL): Median (Range) | 2.5 (0-10.0) | 2.7 (0-10.0) |
| Urine M-protein (mg/24 hours): Median (Range) | 107 (0-24883) | 66 (0-39657) |
| Median Months Since Diagnosis | 35.2 | 37.5 |
| % Prior Therapy | ||
| One | 34 | 34 |
| More than one | 66 | 66 |
| Prior Systemic Therapies for Multiple Myeloma | ||
| Corticosteroid (%) | 99 | >99 |
| Anthracyclines | 68 | 67 |
| Alkylating agent (%) | 92 | 90 |
| Thalidomide/lenalidomide (%) | 40 | 43 |
| Stem cell transplantation (%) | 57 | 54 |
The primary endpoint in this study was time to progression (TTP). TTP was defined as the time from randomization to the first occurrence of progressive disease or death due to progressive disease. The combination arm demonstrated significant improvement in TTP. As the prespecified primary objective was achieved at the interim analysis, patients in the bortezomib monotherapy group were then allowed to receive the DOXIL + bortezomib combination. Survival continued to be followed after the interim analysis and survival data are not mature at this time. Efficacy results are as shown in Table 18 and Figure 1.
Table 18: Efficacy of DOXIL in combination with bortezomib
in the treatment of patients with multiple myeloma
| Endpoint | DOXIL + bortezomib n=324 |
Bortezomib n=322 |
| Time to Progressiona | ||
| Progression or death due to progression (n) | 99 | 150 |
| Censored (n) | 225 | 172 |
| Median in days (months) | 282 (9.3) | 197 (6.5) |
| 95% CI | 250;338 | 170;217 |
| Hazard ratiob | 0.55 | |
| (95% CI) | (0.43, 0.71) | |
| p-valuec | < 0.0001 | |
| Response (n)d | 303 | 310 |
| % Complete Response (CR) | 5 | 3 |
| %Partial Response (PR) | 43 | 40 |
| %CR + PR | 48 | 43 |
| p-valuee | 0.251 | |
| Median Duration of Response (months) | 10.2 | 7.0 |
| (95% CI) | (10.2;12.9) | (5.9;8.3) |
| a Kaplan Meier estimate. b Hazard ratio based on stratified Cox proportional hazards regression. A hazard ratio < 1 indicates an advantage for DOXIL+bortezomib. c Stratified log-rank test. d RR as per EBMT criteria. e Cochran-Mantel-Haenszel test adjusted for the stratification factors. |
||
Time to progression outcomes were consistent with the overall result across most subgroups defined by patient demographic and baseline characteristics. There were too few Blacks or Asian patients to adequately assess differences in effects for the race subgroup.
Figure 1- Time to Progression Kaplan-Meier Curve
 |
Last updated on RxList: 7/8/2008
Patients and patients' caregivers should be informed of the expected adverse effects of DOXIL, particularly hand-foot syndrome, stomatitis, and neutropenia and related complications of neutropenic fever, infection, and sepsis.
Hand-Foot Syndrome (HFS): Patients who experience tingling or burning, redness, flaking, bothersome swelling, small blisters, or small sores on the palms of their hands or soles of their feet (symptoms of Hand-Foot Syndrome) should notify their physician.
Stomatitis: Patients who experience painful redness, swelling, or sores in the mouth (symptoms of stomatitis) should notify their physician.
Fever and Neutropenia: Patients who develop a fever of 100.5°F or higher should notify their physician.
Nausea, vomiting, tiredness, weakness, rash, or mild hair loss: Patients who develop any of these symptoms should notify their physician.
Following its administration, DOXIL may impart a reddish-orange color to the urine and other body fluids. This nontoxic reaction is due to the color of the product and will dissipate as the drug is eliminated from the body.
Last updated on RxList: 6/19/2007
IMPORTANT NOTE: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your health care professional. Always seek the advice of your health care professional if you have any questions about this product or your medical condition. This information is not intended as individual medical advice and does not substitute for the knowledge and judgment of your health care professional. This information does not contain any assurances that this product is safe, effective, or appropriate for you.
DOXORUBICIN LIPOSOMAL - INJECTION
(dox-oh-REW-beh-sin lye-poe-SEW-mull)
COMMON BRAND NAME(S): Doxil
WARNING: Liposomal doxorubicin may cause heart problems, including possibly fatal heart failure. Heart problems may occur during liposomal doxorubicin therapy or months to years after receiving this medication. Your risk of developing heart problems depends on your dose, medical history (including previous heart disease, radiation therapy in the chest area), and previous use of this and other drugs (including daunorubicin and cyclophosphamide). Children are at higher risk and should be monitored later in life for delayed heart problems. See also Side Effects section.
This medication may cause certain severe blood disorders (bone marrow suppression leading to low red blood cells/white blood cells /platelets). This can lower your body's ability to fight infection and stop bleeding. Tell your doctor immediately if you develop any signs of infection (e.g., fever, chills, persistent sore throat), unusual tiredness, or easy bleeding/bruising.
While this drug is first being given into your vein, this medication may cause severe (rarely fatal) reactions, including allergic reactions. Tell your doctor immediately if you experience flushing, trouble breathing, swelling of the face, tightness in the chest/throat, chills, back pain, severe dizziness, or fast heartbeat. See also Side Effects section.
Tell your doctor if you have liver problems because the dose may need to be decreased.
Your doctor will closely monitor you while you are being treated with this medication.
Different types of this medication work in different ways. Do not switch types of this medication without your doctor's permission.
USES: Liposomal doxorubicin is an anthracycline-type chemotherapy drug that is used alone or with other treatments/medications to treat certain types of cancer (e.g., ovarian cancer, AIDS-related Kaposi's sarcoma, multiple myeloma). It works by slowing or stopping cancer cell growth.
OTHER USES: This section contains uses of this drug that are not listed in the approved professional labeling for the drug but that may be prescribed by your health care professional. Use this drug for a condition that is listed in this section only if it has been so prescribed by your health care professional.
This medication may also be used to treat breast cancer.
HOW TO USE: This medication is given by injection into a vein over 30-60 minutes or longer by a health care professional. Before injecting each dose, clean the injection site with rubbing alcohol. The injection should start slowly (1 milligram or less per minute) to decrease the risks from possible serious reactions. This medication should not be injected into a muscle or beneath the skin. Notify your doctor immediately if redness, pain, or swelling occur at or near the injection site.
The dosage is based on your medical condition, body size, and response to therapy.
Follow all instructions for proper mixing, dilution with the correct IV fluids, and injection. The final product should be hazy and reddish in color. Before using, check this medication visually for particles. If particles are present, do not use the liquid. Do not use an in-line filter when giving this medication. If you have questions regarding the use of this medication, consult the pharmacist.
If this medication touches your skin, immediately and completely wash skin with soap and water. If this medication gets in your eye, open the eyelids and flush with plenty of water for 15 minutes. Seek immediate medical attention.
Family members and caregivers should take precautions (e.g., wear gloves) to prevent contact with the patient's urine or other body fluid for at least 5 days after treatment. Learn how to store and discard needles, medical supplies and medical waste safely. Consult your pharmacist.
Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.
This medication may give a reddish-orange color to your urine, tears, and sweat. This is a normal effect of the drug and should not be mistaken for blood in your urine.
Treatment with this drug may sometimes cause your hands/feet to develop a skin reaction called hand-foot syndrome (palmar-plantar erythrodysesthesia). Notify your doctor promptly if you experience swelling, pain, redness, dryness, peeling, blisters, or tingling/burning of the hands/feet. The symptoms can be made worse by heat/pressure on your hands/feet. Avoid prolonged sun exposure, tanning booths, and sunlamps, as well as unnecessary exposure to heat (e.g., hot dishwater, long hot baths). Avoid pressure on elbows, knees, and soles of feet (e.g., leaning on elbows, kneeling, long walks). Wear loose clothing. Depending on how severe your hand-foot syndrome is, your doctor may give you something to reduce the symptoms, or decrease or delay your next dose of liposomal doxorubicin.
Temporary hair loss may occur. Normal hair growth should return several months after treatment has ended.
Tell your doctor immediately if any of these unlikely but serious side effects occur: drowsiness, trouble sleeping, mental/mood changes (e.g., anxiety, confusion, depression), cough/hoarseness, redness/pain/swelling of arms/legs, eye redness/itching, unusual tiredness, swelling of ankles/feet, painful/difficult urination, stomach/abdominal pain, yellowing of the skin/eyes, dark urine.
Painful swelling or sores on the lips, mouth and throat may occur. To decrease the risk, limit hot foods and drinks, brush your teeth carefully, avoid using mouthwash that contains alcohol, and rinse your mouth frequently with cool water.
Tell your doctor immediately if any of these rare but very serious side effects occur: black/tarry stools, bloody mucus or discharge in stools, vision changes (e.g., blindness), fast/irregular heartbeat, shortness of breath.
Seek immediate medical attention if this rare but very serious side effect occurs: chest pain.
Within days to weeks after doxorubicin treatment, a serious skin reaction that looks likes a severe sunburn (radiation recall) may develop on any area of skin that has been previously treated with radiation. Tell your doctor immediately if you develop skin redness, pain, tenderness, swelling, peeling, or blisters. Your doctor may prescribe medication to help your skin heal faster and reduce the swelling. Sunlight may worsen any skin reactions that may occur while you are using this drug. Avoid prolonged sun exposure, tanning booths and sunlamps. Use a sunscreen and wear protective clothing when outdoors.
In children, radiation recall may occur in the lungs. Tell the doctor immediately if you notice wheezing or trouble breathing in the child.
Very rarely, people with cancer who are treated with this type of medication have developed other cancers (e.g., secondary leukemia). Your risk is greater if you have received certain types of chemotherapy or radiation therapy. Consult your doctor for more details.
A very serious allergic reaction to this drug is unlikely, but fatal reactions have rarely occurred. Seek immediate medical attention if you notice symptoms of a serious allergic reaction, which may include: rash, itching, swelling, severe dizziness, trouble breathing.
This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.
Contact your doctor for medical advice about side effects. The following numbers do not provide medical advice, but in the US you may report side effects to the Food and Drug Administration (FDA) at 1-800-FDA-1088. In Canada, you may call Health Canada at 1-866-234-2345.
PRECAUTIONS: Before using liposomal doxorubicin, tell your doctor or pharmacist if you are allergic to it; or to doxorubicin; or to other drugs containing polyethylene glycol; or to lincomycin; or if you have any other allergies.
This medication should not be used if you have certain medical conditions. Before using this medicine, consult your doctor or pharmacist if you have: a history of receiving your total maximum dose of any anthracycline-type drug (e.g., doxorubicin, idarubicin, daunorubicin, mitoxantrone).
Before using this medication, tell your doctor or pharmacist your medical history, especially of: anemia, gout, heart problems, infection, liver problems, radiation treatment (especially to the chest area), kidney problems, a certain immune system problem (neutropenia), low platelet count (thrombocytopenia).
Do not have immunizations/vaccinations without the consent of your doctor, and avoid contact with people who have recently received oral polio vaccine.
To lower the chance of getting cut, bruised or injured, use caution with sharp objects like safety razors and nail cutters, and avoid activities such as contact sports. Use a soft-bristle toothbrush to lower the risk of bleeding gums.
Wash your hands well to prevent the spread of infections.
This drug may make you dizzy or drowsy; use caution while engaging in activities requiring alertness such as driving or using machinery. Limit alcoholic beverages.
Caution is advised if using liposomal doxorubicin in children because they may be more sensitive to its effects, especially on the heart.
This medication is not recommended for use during pregnancy. It may harm an unborn baby. It is recommended that men and women use two effective forms of birth control (e.g., condoms and birth control pills) while being treated with this medication and for some time afterward. Consult your doctor for more details and to discuss reliable forms of birth control.
It is not known whether this drug passes into breast milk. Because of the potential risk to the infant, breast-feeding while using this drug is not recommended. Consult your doctor before breast-feeding.
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription/herbal products you may use, especially of: calcium channel blockers (e.g., verapamil, nifedipine), cyclosporine, digoxin, progesterone, phenobarbital, phenytoin, streptozocin, zidovudine.
Avoid eating foods or products containing turmeric (curcumin) while being treated with liposomal doxorubicin. It may decrease this medication's effects. Consult your doctor or pharmacist for more details.
This document does not contain all possible interactions. Therefore, before using this product, tell your doctor or pharmacist of all the products you use. Keep a list of all your medications with you, and share the list with your doctor and pharmacist.
OVERDOSE: If overdose is suspected, contact your local poison control center or emergency room immediately. US residents can call the US national poison hotline at 1-800-222-1222. Canadian residents should call their local poison control center directly. Symptoms of overdose may include: unexplained bleeding.
NOTES: Laboratory and/or medical tests (e.g., complete blood counts, heart studies, liver function tests) should be performed regularly to monitor your progress or check for side effects. Consult your doctor for more details. Keep all your medical and laboratory appointments.
MISSED DOSE: For the most benefit, it is important to receive each scheduled dose of this medication as directed. If you miss a dose, contact your doctor to establish a new dosing schedule.
STORAGE: Before mixing, refrigerate the dry powder between 36-46 degrees F (2-8 degrees C) in the original container. Protect from light. Do not freeze. Once prepared, this medication may be refrigerated and should be used within 24 hours.
Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company for more details about how to safely discard your product.
MEDICAL ALERT: Your condition can cause complications in a medical emergency. For enrollment information call MedicAlert at 1-800-854-1166 (USA), or 1-800-668-1507 (Canada).
Information last revised July 2008 Copyright(c) 2008 First DataBank, Inc.
Here is a collection of user reviews for the medication Doxil sorted by most helpful. 
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.
 |
RxList does not provide medical advice, diagnosis or treatment. See additional information.
Updated & New